ArticlemedRxiv : the preprint server for health sciences2026
Heart Stress, Frailty and Mortality Risk in two prospective cohorts.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Importance: Frailty is a multisystem syndrome that reflects age-related physiological decline, underscoring the need for more biologically informed risk stratification within frailty assessments. Frailty and heart stress (HS) are individually associated with increased mortality risk, but their combined effects remain practically unexplored. Objective: To evaluate whether the combined exposure to frailty and HS is associated with an increased risk of mortality. Design Setting and Participants: This prospective cohort study used data from the US National Health and Nutrition Examination Survey (NHANES) and the Health and Retirement Study (HRS). Participants with complete data on frailty and HS were included. Analyses was performed between May 2025 and October 2025. Exposure: Frailty was assessed using three frailty indices (FI) based on self-reported items (FI-Self-report), blood biomarkers (FI-Lab), and their combination (FI-Combined). HS was defined by age-adjusted elevation in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Participants were estimate into four groups according to baseline frailty and HS status. Main Outcomes and Measures: The primary outcome was all-cause mortality. Cox proportional hazard models were employed to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs). Results: A total of 12,252 participants from NHANES (mean age 49.91 years, 52.18% female), and 9,488 participants from HRS (mean age 69.16 years, 58.97% female) were included. Compared with those having neither frailty nor HS, participants with frailty and/or HS showed significantly elevated mortality risk in both cohorts, with HRs ranging from 1.81 to 5.54. The highest mortality risk was observed in participant with both frailty and HS, the HRs were 3.58 (95% CI: 3.20-4.01) for FI Self Report, 3.43 (95% CI: 3.04-3.86) for FI Lab, and 4.15 (95% CI: 3.70-4.67) for FI Combined in NHANES; the corresponding HRs were 5.02 (95% CI: 4.38-5.76), 4.73 (95% CI: 4.13-5.41), and 5.54 (95% CI: 4.84-6.35) in HRS, respectively. Conclusions and Relevance: Co-occurrence of frailty and HS is common, and jointly associated with increased mortality risk in the general population. These findings support integrating HS into frailty assessments to improve mortality risk stratification and guide targeted interventions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.